Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Canagliflozin (TA-7284)

The patients will receive Canagliflozin orally for 52 weeks

DRUG

GLP-1 analogue

Trial Locations (4)

Reserch site, Chūbu

Reserch site, Hokkaido

Reserch site, Kanto

Reserch site, Kinki